Is hormone therapy safe for menopause? For more than twenty years, a bold "black box" warning on every estrogen prescription told women it might not be. That changed. In November 2025 the FDA announced it was removing most of those warnings from menopausal hormone therapy, and the updated labels took effect in early 2026. If you avoided hormones because of that warning, or your doctor steered you away from them, it is worth taking a fresh look. Here is what actually changed, what did not, and what it means for women in Wilmington and Leland who are living with hot flashes, poor sleep, brain fog, and the rest of the menopause transition.

The short answer

• The FDA removed the boxed warnings about heart disease, stroke, breast cancer, and probable dementia from menopausal hormone therapy labels.
• One boxed warning remains: estrogen taken alone (without progesterone) by a woman who still has her uterus can raise the risk of endometrial cancer. That is why women with a uterus are prescribed progesterone alongside estrogen.
• Timing matters. The new labeling emphasizes that the benefit and risk balance is most favorable when therapy starts before age 60 or within about 10 years of menopause.
• Hormone therapy is still a prescription, not a supplement. The right choice depends on your personal and family history, your symptoms, and your labs.

Why the warning existed in the first place

The boxed warning dates back to 2003, shortly after early results from the Women's Health Initiative (WHI) study made headlines linking hormone therapy to breast cancer, heart attacks, and stroke. Almost overnight, millions of women stopped treatment, and a generation of doctors stopped prescribing it.

The problem was who the study looked at. Most WHI participants were in their 60s and 70s, often many years past menopause, and they took older hormone formulations. Later analyses of the same data, along with newer research, showed a very different picture for women who start therapy closer to menopause: the absolute risks are small, and for many women the benefits for symptoms, sleep, and bone health outweigh them. After an FDA expert panel reviewed the evidence in July 2025, the agency concluded the blanket warning was overstating risk for the women most likely to use these medications.

What changed on the label, and what did not

The labeling update applies to FDA-approved estrogen and progestogen products, including combined estrogen and progesterone therapy, estrogen-only therapy, and low-dose vaginal estrogen. The changes remove the boxed warnings for:

• Cardiovascular disease (heart attack and stroke)
• Breast cancer
• Probable dementia

What stays the same: the endometrial cancer warning for estrogen-only therapy in women with a uterus, and the general principle that hormone therapy should be individualized. Removing a warning does not mean hormones are right for everyone. Women with a history of certain cancers, blood clots, stroke, or active liver disease still need a careful conversation, and some are not candidates at all.

The vaginal estrogen change is a big deal

Low-dose vaginal estrogen (creams, tablets, and rings) treats dryness, painful intimacy, urinary urgency, and recurrent urinary tract infections. Very little of it reaches the bloodstream, yet for years it carried the same frightening warning as systemic pills. Many women never filled the prescription after reading the insert. With that warning removed, one of the safest and most effective treatments for genitourinary symptoms of menopause is finally labeled like it. If bladder leaks are part of the picture, pairing local estrogen with a pelvic floor treatment like Emsella can make a noticeable difference.

Who is a good candidate for hormone therapy now?

Current guidance points to the best benefit and risk balance for women who:

• Are under 60, or within about 10 years of their final period
• Have moderate to severe hot flashes, night sweats, or sleep disruption
• Are dealing with mood changes, brain fog, joint aches, or low libido tied to the transition
• Have vaginal dryness or urinary symptoms
• Are concerned about bone loss

Women in perimenopause, the years of irregular cycles and fluctuating hormones before periods stop, often have symptoms that are just as disruptive. We cover that stage in depth in Perimenopause in Your 40s: The Symptoms Women Miss.

Does this apply to bioidentical hormones?

"Bioidentical" means the hormone is molecularly identical to what your body makes, such as estradiol and micronized progesterone. Several FDA-approved products are bioidentical, and those are covered by the new labeling. Compounded hormones, which are custom-mixed by a pharmacy, are not FDA-approved products and do not carry FDA labels at all, so the label change does not apply to them directly. The underlying science on timing and individual risk still does. At BioSymmetry Wilmington, bioidentical hormone therapy for women starts with lab testing and a full history, and we talk through which delivery method (creams, capsules, injections, or pellets) fits your body and your risks. Our guide to BHRT administration methods compares the options.

What hormone therapy can and cannot do

Hormone therapy remains the most effective treatment for hot flashes and night sweats, and it helps protect bone density. Many women also report better sleep, steadier mood, and improved comfort with intimacy. It is not a proven way to prevent heart disease or Alzheimer's disease, and experts caution against marketing that suggests otherwise. A realistic plan also looks at thyroid function, metabolic health, strength training, and sleep, which is why we often check thyroid levels alongside sex hormones.

Questions to bring to your consultation

• Based on my age and time since menopause, where do I fall on the benefit and risk curve?
• Do I need progesterone, and why?
• Would a patch, cream, or pellet be safer for me than a pill?
• Is local vaginal estrogen enough for my symptoms, or do I need systemic therapy?
• How often will we recheck labs and adjust my dose?

Frequently asked questions

Did the FDA say hormone therapy is completely safe? No. The FDA removed boxed warnings that overstated risks for most women, but hormone therapy still has risks that depend on your age, health history, and the type of therapy. Individualized evaluation is still required.

When did the FDA remove the black box warning on HRT? The FDA announced the change on November 10, 2025, and updated labeling rolled out in early 2026.

Is it too late to start hormone therapy after 60? Not always. The most favorable balance is before 60 or within 10 years of menopause, but women over 60 with persistent symptoms can still be evaluated. The decision depends on your cardiovascular and breast health history.

Does hormone therapy cause breast cancer? Combined estrogen and progestogen therapy is associated with a small increase in breast cancer risk with longer use, while estrogen alone in women without a uterus has not shown the same increase. For most women starting near menopause, the absolute risk is low, and your provider will weigh it against your personal and family history.

Is vaginal estrogen safe? Low-dose vaginal estrogen is absorbed in very small amounts and is considered low risk for most women. The FDA removed its boxed warning in this update.

Take a second look, with a real plan

If fear of the old warning kept you from treating symptoms that are affecting your sleep, work, and relationships, you deserve an updated conversation. The team at BioSymmetry Wilmington offers hormone testing and personalized treatment for women across Wilmington, Leland, and the Cape Fear region. Schedule a consultation to find out whether hormone therapy makes sense for you.

This article is for general education and is not medical advice. Individual results vary. Please consult a qualified provider about your specific health needs.